Anhui Anke Biotechnology (Group) Co (SZSE:300009) Construction In Progress: ¥530 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:300009 Anhui Anke Biotechnology (Group) Co Ltd SZSE:300009
90 GF Score
Price ¥8.55
GF Value ¥9.68
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Anhui Anke Biotechnology (Group) Co Construction In Progress?

Anhui Anke Biotechnology (Group) Co SZSE:300009 +1.42% 90 Construction In Progress is ¥530 Mil as of Jun. 2026. GuruFocus rates SZSE:300009 with a GF Score™ of 90/100 and a GF Value™ of ¥9.68 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Anhui Anke Biotechnology (Group) Co's quarterly construction in progress declined from Dec. 2025 (¥621 Mil) to Mar. 2026 (¥589 Mil) and declined from Mar. 2026 (¥589 Mil) to Jun. 2026 (¥530 Mil).

Anhui Anke Biotechnology (Group) Co's annual construction in progress increased from Dec. 2023 (¥673 Mil) to Dec. 2024 (¥800 Mil) but then declined from Dec. 2024 (¥800 Mil) to Dec. 2025 (¥621 Mil).

Anhui Anke Biotechnology (Group) Co Construction In Progress Historical Data

* Premium members only.

The historical data trend for Anhui Anke Biotechnology (Group) Co's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anhui Anke Biotechnology (Group) Co Construction In Progress Chart

Anhui Anke Biotechnology (Group) Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 228.75 445.68 672.51 799.75 620.77

Anhui Anke Biotechnology (Group) Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 838.87 614.99 620.77 588.70 529.79
SZSE:300009
90GF Score
Anhui Anke Biotechnology (Group) Co Ltd SZSE:300009
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anhui Anke Biotechnology (Group) Co Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ¥530 Mil mean?
Anhui Anke Biotechnology (Group) Co (SZSE:300009) has a Construction In Progress of ¥530 Mil as of Jun. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Anhui Anke Biotechnology (Group) Co and its competitors.
Is Anhui Anke Biotechnology (Group) Co's Construction In Progress too high?
Anhui Anke Biotechnology (Group) Co's current Construction In Progress is ¥530 Mil. Overall, Anhui Anke Biotechnology (Group) Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anhui Anke Biotechnology (Group) Co's Construction In Progress compare to VRTX and REGN?
Anhui Anke Biotechnology (Group) Co's Construction In Progress of ¥530 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Anhui Anke Biotechnology (Group) Co and its competitors. Anhui Anke Biotechnology (Group) Co's current Construction In Progress is ¥530 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anhui Anke Biotechnology (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Anhui Anke Biotechnology (Group) Co (SZSE:300009) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥9.68, compared to a current price of ¥8.55 — trading 11.7% below its estimated fair value. The current Construction In Progress is ¥530 Mil. Anhui Anke Biotechnology (Group) Co's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Anhui Anke Biotechnology (Group) Co (SZSE:300009), the current Construction In Progress is ¥530 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anhui Anke Biotechnology (Group) Co (SZSE:300009) Overvalued in 2026?

Based on GuruFocus' analysis, Anhui Anke Biotechnology (Group) Co stock appears to be undervalued. The current stock price of ¥8.55 is trading 11.7% below its estimated GF Value™ of ¥9.68. GuruFocus considers Anhui Anke Biotechnology (Group) Co to be Modestly Undervalued.

Key valuation signals for SZSE:300009:

  • Construction In Progress: ¥530 Mil
  • GF Value™: ¥9.68 vs. price of ¥8.55 (11.7% below fair value)
  • GF Score™: 90/100 with 2 warning signs

No single metric tells the full story. See the SZSE:300009 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Anhui Anke Biotechnology (Group) Co Business Description

Address No.9 Changjiang Road, Hefei High-tech Zone, Customs Road 669, Hefei, CHN, 230088
Anhui Anke Biotechnology (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceuticals and health-care products. The Company distributes its product in both domestic and overseas markets. The company operates in more than 30 provinces in China.
90GF Score

Get the complete analysis for SZSE:300009

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥8.55
Price
¥9.68
GF Value